tirzepatide regulatory filings FDA approves tirzepatide, Eli Lilly's new type 2 diabetes drug, and the company shares an estimated price FDA says shortage of GLP-1

SURMOUNT-2: Confirmed weight loss and metabolic benefit in people with diabetes In adults with obesity or overweight with Type 2 diabetes, tirzepatide met co-primary endpoints, showing superior weight loss versus placebo at 72 weeks, with meaningful reductions in weight, high percentages achieving 5% weight loss, and improvements in glycaemic and metabolic outcomes

Its the only GLP-1 medication available as a tablet rather than an injection

For anyone tracking the broader category of medications that target liver fat, understanding how mazdutide compares to retatrutide provides additional context on the competitive landscape

Our findings also provide directions for future research in other target populations, the researchers wrote

The strategies for managing tirzepatide side effects should not be applied to symptoms that might indicate infection